From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

Main Article Content

Emilio Bajetta (1*), Giuseppe Procopio (2), Sara Pusceddu (3), Filippo Pietrantonio (4), Massimo Milione (5), Marco Maccauro (6), Elena Verzoni (7), Valentina Guadalupi (8), Marco Platania (9)

1 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
2 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
3 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
4 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
5 Pathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
6 Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
7 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
8 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
9 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
(*) Corresponding Author:
Emilio Bajetta
emilio.bajetta@istitutotumori.mi.it

Abstract

Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Bajetta, E., Procopio, G., Pusceddu, S., Pietrantonio, F., Milione, M., Maccauro, M., Verzoni, E., Guadalupi, V., & Platania, M. (2011). From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 3(2), 79-87. https://doi.org/10.4081/oncol.2009.79